Meeting
2019 ASCO Annual Meeting
Outcomes of patients (pts) ≥ 65 years of age in ZUMA-1, a pivotal phase 1/2 study of axicabtagene ciloleucel (axi-cel) in refractory large B cell lymphoma (LBCL).
Authors
Sattva Swarup Neelapu
The University of Texas MD Anderson Cancer Center, Houston, TX
Sattva Swarup Neelapu , Caron A. Jacobson , Olalekan O. Oluwole , Javier Munoz , Abhinav Deol , David Bernard Miklos , Nancy L. Bartlett , Ira Braunschweig , Yizhou Jiang , Jenny J. Kim , Lianqing Zheng , John M. Rossi , Frederick Lundry Locke
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT02348216
Citation
J Clin Oncol 37, 2019 (suppl; abstr 7555)
DOI
10.1200/JCO.2019.37.15_suppl.7555
Abstract #
7555
Poster Bd #
309
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Axicabtagene ciloleucel (axi-cel) in combination with rituximab (Rtx) for the treatment (Tx) of refractory large B-cell lymphoma (R-LBCL): Outcomes of the phase 2 ZUMA-14 study.
First Author: Paolo Strati
Poster
2020 ASCO Virtual Scientific Program
Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1.
First Author: Frederick Lundry Locke
Poster
2018 ASCO Annual Meeting
Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucel (Axi-Cel) in patients (Pts) with refractory large B-cell lymphoma.
First Author: Frederick Lundry Locke
Poster
2017 ASCO Annual Meeting
Clinical and biologic covariates of outcomes in ZUMA-1: A pivotal trial of axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (r-NHL).
First Author: Frederick Lundry Locke